These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 16148087)

  • 1. Directing transition from innate to acquired immunity: defining a role for IL-6.
    Jones SA
    J Immunol; 2005 Sep; 175(6):3463-8. PubMed ID: 16148087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 and chronic inflammation.
    Gabay C
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S3. PubMed ID: 16899107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms.
    McLoughlin RM; Hurst SM; Nowell MA; Harris DA; Horiuchi S; Morgan LW; Wilkinson TS; Yamamoto N; Topley N; Jones SA
    J Immunol; 2004 May; 172(9):5676-83. PubMed ID: 15100312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmacytoid dendritic cells act as the most competent cell type in linking antiviral innate and adaptive immune responses.
    Zhang Z; Wang FS
    Cell Mol Immunol; 2005 Dec; 2(6):411-7. PubMed ID: 16426490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
    Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
    Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gp130 signaling promotes development of acute experimental colitis by facilitating early neutrophil/macrophage recruitment and activation.
    Sander LE; Obermeier F; Dierssen U; Kroy DC; Singh AK; Seidler U; Streetz KL; Lutz HH; Müller W; Tacke F; Trautwein C
    J Immunol; 2008 Sep; 181(5):3586-94. PubMed ID: 18714032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and molecular mechanisms involved in the resolution of innate leukocyte inflammation.
    Rahtes A; Geng S; Lee C; Li L
    J Leukoc Biol; 2018 Sep; 104(3):535-541. PubMed ID: 29688584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of grass carp interleukin-6 receptor and the agonistic activity of its soluble form in head kidney leucocytes.
    Wang X; Guo Y; Wen C; Lv M; Gan N; Zhou H; Zhang A; Yang K
    Fish Shellfish Immunol; 2019 Mar; 86():1072-1080. PubMed ID: 30576778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.
    Sikorski K; Czerwoniec A; Bujnicki JM; Wesoly J; Bluyssen HA
    Cytokine Growth Factor Rev; 2011 Aug; 22(4):211-9. PubMed ID: 21752694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-27R Signaling Mediates Early Viral Containment and Impacts Innate and Adaptive Immunity after Chronic Lymphocytic Choriomeningitis Virus Infection.
    Harker JA; Wong KA; Dallari S; Bao P; Dolgoter A; Jo Y; Wehrens EJ; Macal M; Zuniga EI
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 and its receptor: from bench to bedside.
    Scheller J; Rose-John S
    Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases.
    Rincon M
    Trends Immunol; 2012 Nov; 33(11):571-7. PubMed ID: 22883707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity.
    Murphy JE; Robert C; Kupper TS
    J Invest Dermatol; 2000 Mar; 114(3):602-8. PubMed ID: 10692124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
    Garbers C; Rose-John S
    Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling.
    Hoge J; Yan I; Jänner N; Schumacher V; Chalaris A; Steinmetz OM; Engel DR; Scheller J; Rose-John S; Mittrücker HW
    J Immunol; 2013 Jan; 190(2):703-11. PubMed ID: 23241882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 as a keystone cytokine in health and disease.
    Hunter CA; Jones SA
    Nat Immunol; 2015 May; 16(5):448-57. PubMed ID: 25898198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.